LB-S&T-12 OPEN -LABEL PHASE II STUDY EVALUATING THE EFFICACY OF CONCURRENT ADMINISTRATION OF RADIUM RA 223 DICHLORIDE AND ABIRATERONE ACETATE IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH SYMPTOMATIC BONE METASTASES (ERADICATE)

Concurrent Administration ◽

Open Label ◽

Castration Resistant ◽

Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e16546 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e16546-e16546 ◽

Cited By ~ 4

Author(s):

Luke T. Nordquist ◽

Neal D. Shore

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Phase Ii Study ◽

Abiraterone Acetate ◽

Concurrent Administration ◽

Open Label ◽

Castration Resistant ◽

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Open Label ◽

Castration Resistant ◽

Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2020.02.015 ◽

2020 ◽

Vol 18 (5) ◽

pp. 416-422 ◽

Cited By ~ 1

Author(s):

Neal D. Shore ◽

Paul F. Schellhammer ◽

Ronald F. Tutrone ◽

Neil F. Mariados ◽

Stacey S. Harrelson

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Concurrent Administration ◽

Open Label ◽

Castration Resistant ◽

Radium 223 ◽

A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5103 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5103-TPS5103 ◽

Cited By ~ 1

Author(s):

Daniel Peter Petrylak ◽

Julie A. Rosenberg ◽

Vittorio Luigi Garosi ◽

Jonathan Siegel ◽

Jonathan Goldin

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Abiraterone Acetate ◽

Efficacy And Safety ◽

Open Label ◽

Castration Resistant ◽

Radium 223 ◽

A Phase 2, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.07.013 ◽

2021 ◽

Author(s):

Nobuaki Matsubara ◽

Hirotsugu Uemura ◽

Satoshi Nagamori ◽

Hiroyoshi Suzuki ◽

Hiroji Uemura ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Phase 2 ◽

Open Label ◽

Castration Resistant

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases

The Prostate ◽

10.1002/pros.23893 ◽

2019 ◽

Vol 79 (14) ◽

pp. 1683-1691 ◽

Cited By ~ 2

Author(s):

Oliver Sartor ◽

Daniel Heinrich ◽

Neil Mariados ◽

Maria José Méndez Vidal ◽

Daniel Keizman ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 1 ◽

Open Label ◽

Castration Resistant ◽

Radium 223 ◽

Radium-223 re-treatment in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up from an international, open-label, phase 1/2 study

European Urology Supplements ◽

10.1016/s1569-9056(18)31441-6 ◽

2018 ◽

Vol 17 (2) ◽

pp. e872-e873

Author(s):

D. Heinrich ◽

L. Nordquist ◽

N. Mariados ◽

M.J. Méndez Vidal ◽

D. Keizman ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 1 ◽

Open Label ◽

Castration Resistant ◽

Radium 223 ◽

900 OPEN-LABEL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF PERSONALIZED PEPTIDE VACCINATION (PPV) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER(CRPC)

The Journal of Urology ◽

10.1016/j.juro.2011.02.2609 ◽

2011 ◽

Vol 185 (4S) ◽

Author(s):

Masanori Noguchi ◽

Fukuko Moriya ◽

Shigetaka Suekane ◽

Kei Matsuoka ◽

Gaku Arai ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Peptide Vaccination ◽

Open Label ◽

Castration Resistant ◽

An open label phase I/randomised, double-blind phase II study in metastatic castration resistant Prostate Cancer of AZD5363 in combination with Docetaxel and prednisolone chemotherapy (ProCAID)

http://isrctn.org/> ◽

10.1186/isrctn69139368 ◽

2014 ◽

Author(s):

Study Coordinator

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Double Blind ◽

Castration Resistant ◽

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

Annals of Oncology ◽

10.1093/annonc/mdx331 ◽

2017 ◽

Vol 28 (10) ◽

pp. 2464-2471 ◽

Cited By ~ 17

Author(s):

O. Sartor ◽

D. Heinrich ◽

N. Mariados ◽

M.J. Méndez Vidal ◽

D. Keizman ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Bone Metastases ◽

Open Label ◽

Castration Resistant ◽

Radium 223 ◽